99mTc radiotracers based on human GRP(18-27): Synthesis and comparative evaluation

Journal of Nuclear Medicine

Volumn 54, Issue 10, 2013, Pages 1797-1803

  Marsouvanidis, Panteleimon J ^a,b   Maina, Theodosia ^a   Sallegger, Werner ^c   Krenning, Eric P ^b   De Jong, Marion ^b   Nock, Berthold A ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c piCHEM Research and Development   (Austria)

Author keywords

Gastrin releasing peptide; Gastrin releasing peptide receptor; Tumor imaging

Indexed keywords

BOMBESIN[4 TYROSINE] I 125; GASTRIN RELEASING PEPTIDE RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR[18-27] TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BOMBESIN; DIAGNOSTIC AGENT; GASTRIN RELEASING PEPTIDE; LIGAND; NEUROMEDIN C; PEPTIDE FRAGMENT; TECHNETIUM; TRACER;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CANCER CELL CULTURE; CELL STRAIN PC 3; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SCID MOUSE; STRUCTURE ACTIVITY RELATION; 99MTC RADIOTRACER; ANIMAL; CELL TRANSFORMATION; GASTRIN-RELEASING PEPTIDE RECEPTOR; METABOLISM; SYNTHESIS; TUMOR CELL LINE; TUMOR IMAGING; DIAGNOSTIC USE;

99MTC RADIOTRACER; GASTRIN-RELEASING PEPTIDE; GASTRIN-RELEASING PEPTIDE RECEPTOR; TUMOR IMAGING;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHEMISTRY TECHNIQUES, SYNTHETIC; HUMANS; LIGANDS; MALE; MICE; PEPTIDE FRAGMENTS; RADIOACTIVE TRACERS; TECHNETIUM;

EID: 84887971149     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118695     Document Type: Article

References (24)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
2. Maina T, Nock B, Mather S. Targeting prostate cancer with radiolabelled bombesins. Cancer Imaging. 2006;6:153-157.
3. Sancho V, Di Florio A, Moody TW, Jensen RT. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv. 2011;8:79-134.
4. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
5. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
6. Guinee DG Jr, Fishback NF, Koss MN, Abbondanzo SL, Travis WD. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol. 1994;102:406-414.
7. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31:803-810.
8. Fleischmann A, Waser B, Reubi JC. Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol. 2007;29:421-433.
9. Nanda PK, Pandey U, Bottenus BN, et al. Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol. 2012;39:461-471.
10. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999;81:658-665.
11. 99mTc: a preclinical study. J Med Chem. 2005;48:100-110.
12. Kroog GS, Jensen RT, Battey JF. Mammalian bombesin receptors. Med Res Rev. 1995;15:389-417.
13. 99mTc]demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models. J Med Chem. 2012;55:8364-8374.
14. Uehara H, Gonzalez N, Sancho V, et al. Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs. Peptides. 2011;32:1685-1699.
15. Zhang H, Abiraj K, Thorek DL, et al. Evolution of bombesin conjugates for targeted PET imaging of tumors. PLoS ONE. 2012;7:e44046.
16. 4]bombesin by tumor cells. Prostate. 1994;25:29-38.
17. 111In-DOTA]somatostatin- 14 analogs as potential pansomatostatin-like radiotracers: first results of a preclinical study. EJNMMI Res. 2012;2:25.
18. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-6715.
19. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017-2024.
20. Linder KE, Metcalfe E, Arunachalam T, et al. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites. Bioconjug Chem. 2009;20:1171-1178.
21. Shipp MA, Tarr GE, Chen CY, et al. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA. 1991;88:10662-10666.
22. 14]bombesin(6-14). Clin Cancer Res. 2002; 8:1139-1146.
23. Maina T, Nock BA, Zhang H, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med. 2005;46:823-830.
24. de Jong M, Maina T. Of mice and humans: are they the same? Implications in cancer translational research. J Nucl Med. 2010;51:501-504.